{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:37:26Z","timestamp":1792748246679,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of South Carolina Honors College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"DOI":"10.1007\/s40801-026-00587-1","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:38:20Z","timestamp":1792744700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eluxadoline Utilization in Medicare Part D, 2016\u201323: National Trends, Geographic Variation, Prescriber-Type Patterns, and Spending"],"prefix":"10.1007","author":[{"given":"Avery R.","family":"Hammersmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8561","authenticated-orcid":false,"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-4976","authenticated-orcid":false,"given":"Chao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-9143","authenticated-orcid":false,"given":"Bryan L.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"8","key":"587_CR1","doi-asserted-by":"publisher","first-page":"ITC113","DOI":"10.7326\/ANNALS-25-01965","volume":"178","author":"KB Greer","year":"2025","unstructured":"Greer KB, Sultan S. Irritable bowel syndrome. Ann Intern Med. 2025;178(8):ITC113\u201328. https:\/\/doi.org\/10.7326\/ANNALS-25-01965.","journal-title":"Ann Intern Med"},{"issue":"1","key":"587_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17\u201344. https:\/\/doi.org\/10.14309\/ajg.0000000000001036.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"587_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","volume":"163","author":"A Lembo","year":"2022","unstructured":"Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137\u201351. https:\/\/doi.org\/10.1053\/j.gastro.2022.04.017.","journal-title":"Gastroenterology"},{"issue":"6","key":"587_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1053\/j.gastro.2023.08.010","volume":"165","author":"CV Almario","year":"2023","unstructured":"Almario CV, Sharabi E, Chey WD, Lauzon M, Higgins CS, Spiegel BMR. Prevalence and burden of illness of Rome IV irritable bowel syndrome in the United States: results from a nationwide cross-sectional study. Gastroenterology. 2023;165(6):1475\u201387. https:\/\/doi.org\/10.1053\/j.gastro.2023.08.010.","journal-title":"Gastroenterology"},{"issue":"12","key":"587_CR5","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.cgh.2019.08.016","volume":"17","author":"S Ballou","year":"2019","unstructured":"Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2019.08.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"587_CR6","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1007\/s12325-022-02224-z","volume":"39","author":"B Moshiree","year":"2022","unstructured":"Moshiree B, Heidelbaugh JJ, Sayuk GS. A narrative review of irritable bowel syndrome with diarrhea: a primer for primary care providers. Adv Ther. 2022;39(9):4003\u201320. https:\/\/doi.org\/10.1007\/s12325-022-02224-z.","journal-title":"Adv Ther"},{"issue":"1","key":"587_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/nmo.12716","volume":"28","author":"BE Lacy","year":"2016","unstructured":"Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline: a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28(1):26\u201335. https:\/\/doi.org\/10.1111\/nmo.12716.","journal-title":"Neurogastroenterol Motil"},{"key":"587_CR8","unstructured":"VIBERZI (eluxadoline) [Prescribing information]. Madison, NJ: Allergan USA, Inc.; 2018."},{"key":"587_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2490841","volume":"9","author":"MB Andrews","year":"2025","unstructured":"Andrews MB, Adler DG. Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database. Expert Opin Drug Saf. 2025;9:1\u20137. https:\/\/doi.org\/10.1080\/14740338.2025.2490841.","journal-title":"Expert Opin Drug Saf"},{"key":"587_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474124.2025.2455586","volume":"21","author":"CJ Black","year":"2025","unstructured":"Black CJ, Ford AC. An evidence-based update on the diagnosis and management of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2025;21:1\u201316. https:\/\/doi.org\/10.1080\/17474124.2025.2455586.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"587_CR11","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s10620-022-07700-8","volume":"68","author":"G Piovezani Ramos","year":"2023","unstructured":"Piovezani Ramos G, Camilleri M. Current and future therapeutic options for irritable bowel syndrome with diarrhea and functional diarrhea. Dig Dis Sci. 2023;68(5):1677\u201390. https:\/\/doi.org\/10.1007\/s10620-022-07700-8.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"587_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","volume":"145","author":"LS Dove","year":"2013","unstructured":"Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145(2):329-38 e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.04.006.","journal-title":"Gastroenterology"},{"issue":"2","key":"587_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ajg.2016.542","volume":"112","author":"BD Cash","year":"2017","unstructured":"Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365\u201374. https:\/\/doi.org\/10.1038\/ajg.2016.542.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"587_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/apt.14031","volume":"45","author":"WD Chey","year":"2017","unstructured":"Chey WD, Dove LS, Andrae DA, Covington PS. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two phase 3 studies. Aliment Pharmacol Ther. 2017;45(10):1319\u201328. https:\/\/doi.org\/10.1111\/apt.14031.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"587_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/ajg.2017.72","volume":"112","author":"BE Lacy","year":"2017","unstructured":"Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS. Eluxadoline efficacy in IBS-D patients who report prior loperamide use. Am J Gastroenterol. 2017;112(6):924\u201332. https:\/\/doi.org\/10.1038\/ajg.2017.72.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"587_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa1505180","volume":"374","author":"AJ Lembo","year":"2016","unstructured":"Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1505180.","journal-title":"N Engl J Med"},{"key":"587_CR17","doi-asserted-by":"publisher","first-page":"175628482110017","DOI":"10.1177\/17562848211001725","volume":"14","author":"BD Cash","year":"2021","unstructured":"Cash BD, Lacy BE, Watton C, Schoenfeld PS, Weissman D. Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change. Ther Adv Gastroenterol. 2021;14:17562848211001724. https:\/\/doi.org\/10.1177\/17562848211001725.","journal-title":"Ther Adv Gastroenterol"},{"issue":"11","key":"587_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622317714389","volume":"8","author":"K Barshop","year":"2017","unstructured":"Barshop K, Staller K. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Ther Adv Chronic Dis. 2017;8(11):153\u201360. https:\/\/doi.org\/10.1177\/2040622317714389.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"587_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1056\/NEJMsa1104816","volume":"366","author":"JM Donohue","year":"2012","unstructured":"Donohue JM, Morden NE, Gellad WF, Bynum JP, Zhou W, Hanlon JT, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012;366(6):530\u20138. https:\/\/doi.org\/10.1056\/NEJMsa1104816.","journal-title":"N Engl J Med"},{"issue":"5","key":"587_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1188","volume":"5","author":"TB Hayford","year":"2024","unstructured":"Hayford TB. Role of specialty drugs in rising drug prices for Medicare Part D. JAMA Health Forum. 2024;5(5):e241188. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.1188.","journal-title":"JAMA Health Forum"},{"issue":"4","key":"587_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/1475-6773.14139","volume":"58","author":"BN Ippolito","year":"2023","unstructured":"Ippolito BN, Levy JF. The influence of Medicare Part D on the list pricing of brand drugs. Health Serv Res. 2023;58(4):948\u201352. https:\/\/doi.org\/10.1111\/1475-6773.14139.","journal-title":"Health Serv Res"},{"issue":"8","key":"587_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jamainternmed.2017.1885","volume":"177","author":"SB Dusetzina","year":"2017","unstructured":"Dusetzina SB, Conti RM, Yu NL, Bach PB. Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending. JAMA Intern Med. 2017;177(8):1185\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2017.1885.","journal-title":"JAMA Intern Med"},{"key":"587_CR23","unstructured":"Office USGA. Medicare Part D: CMS Should Monitor Effects of Rebates on Drug Coverage and Spending. Washington, DC: U.S. Government Accountability Office; 2023 September 19. Report No.: GAO-23-107056."},{"issue":"9","key":"587_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1756283X17721152","volume":"10","author":"S Levio","year":"2017","unstructured":"Levio S, Cash BD. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Ther Adv Gastroenterol. 2017;10(9):715\u201325. https:\/\/doi.org\/10.1177\/1756283X17721152.","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00587-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:38:21Z","timestamp":1792744701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":24,"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00587-1","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"21 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Avery R. Hammersmith, Ismaeel Yunusa, Chao Cai, and Bryan L. Love have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized publicly available, de-identified PUFs provided by the CMS. The University of South Carolina Institutional Review Board reviewed the project and determined that it did not constitute human-subjects research (Pro00143086). The study used publicly available aggregate data containing no beneficiary-level identifiers.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}